TriangleHEALTH PROFESSIONAL · SOURCE READING
Involved-Site Radiation Therapy (ISRT)
Source: Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 16, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Primary Refractory or Recurrent Hodgkin Lymphoma in Children and Adolescents
ISRT to sites of recurrent disease may enhance local control if these sites have not been previously irradiated. ISRT is generally administered after high-dose chemotherapy and stem cell rescue.[60] For patients who are not responsive to salvage therapy, ISRT may be considered before HSCT.[61,62] Consolidative ISRT is particularly appropriate in the following situations:[1]
Low-risk patients whose PET scans are negative after standard-dose salvage chemotherapy.
Select standard-risk and/or high-risk patients who are treated with high-dose chemotherapy and HSCT.
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice